=Incyte (INCY) and Merck (MRK) present progression-free survival data from ECHO-202 Trial

Incyte and Merck present progression-free survival data from ECHO-202 Trial 

• Incyte (INCY) and Merck (MRK) announced updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced melanoma.
• Among all patients with advanced melanoma, including treatment-nave and treatment-experienced, data showed an overall response rate of 56% in patients treated with the combination of epacadostat and KEYTRUDA; median progression-free survival was 12.4 months, with PFS rates of 65% at six months, 52% at 12 months, and 49% at 18 months.
• Results were generally consistent across dosing schedules of epacadostat combined with KEYTRUDA, including epacadostat 100 mg BID, the epacadostat dose being studied in the Phase 3 ECHO-301 trial.